Revenue Recognition - (Additional Information) (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended			6 Months Ended		12 Months Ended
	Oct. 31, 2023	May 31, 2021	Jun. 30, 2025	Mar. 31, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024	Dec. 31, 2024
Related Party Transaction [Line Items]
Number of milestones								two
Milestones require payments				$ 6,000
Company is owed in milestone payments						$ 8,000
Revenue			$ 4,833		$ 1,435	7,917	$ 1,435
Research and development			27,362		29,247	51,963	42,089
Accounts receivable			2,693			2,693		$ 12,722
Contract Assets						$ 0
Revenue, performance obligation satisfied over time, method used, description						The Company expects to recognize all of this balance as revenue as research and development services are provided over the next 4 years.
Contract with customer liability revenue recognized						$ 9,700
Contract Liability			4,500			4,500
Capitalized contract cost			2,000			2,000
Research And Development Service Revenue [Member]
Related Party Transaction [Line Items]
Contract Liability			22,184			22,184
License [Member]
Related Party Transaction [Line Items]
Milestones require payments								$ 2,000
Revenue			3,595		$ 1,435	6,679	$ 1,435
Product Revenue [Member]
Related Party Transaction [Line Items]
Revenue						1,200
Innovent [Member]
Related Party Transaction [Line Items]
Accounts receivable			1,200			1,200
Innovent [Member] \| Research And Development Service Revenue [Member]
Related Party Transaction [Line Items]
Revenue			2,200			4,100
Innovent [Member] \| Product Revenue [Member]
Related Party Transaction [Line Items]
Revenue			900			1,700
Innovent [Member] \| Royalty Revenue [Member]
Related Party Transaction [Line Items]
Revenue			200			500
Innovent [Member] \| Anheart [Member]
Related Party Transaction [Line Items]
Repayments of NonRefundable Upfront Cash Payment		$ 12,000
Achievement of commercial milestones		105,000
achievement of additional regulatory milestones		$ 17,000
Nk [Member]
Related Party Transaction [Line Items]
Received a non-refundable upfront cash payment	$ 25,000
Achievement of commercial milestones	$ 35,000
Research and development			200			400
Accounts receivable			$ 100			$ 100

Nuvation Bio Inc. 10-Q